Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes

Open Access

Peer-reviewed

Research Article

Aarti Ramanathan,

Affiliation Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
⨯
Viktoria Gusarova,

Affiliation Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
⨯
Neil Stahl,

Affiliation Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
⨯
Anne Gurnett-Bander,

Affiliation Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
⨯
Christos A. Kyratsous

* E-mail: christos.kyratsous@regeneron.com

Affiliation Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
⨯

Reader Comments (0)

Monoclonal antibodies
Is the Subject Area "Monoclonal antibodies" applicable to this article?

Thanks for your feedback.
Hepatitis C virus
Is the Subject Area "Hepatitis C virus" applicable to this article?

Thanks for your feedback.
Antibody therapy
Is the Subject Area "Antibody therapy" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
Antibody isotypes
Is the Subject Area "Antibody isotypes" applicable to this article?

Thanks for your feedback.
Flow cytometry
Is the Subject Area "Flow cytometry" applicable to this article?

Thanks for your feedback.
Luciferase
Is the Subject Area "Luciferase" applicable to this article?

Thanks for your feedback.